Back to Search Start Over

Electroanatomical mapping after cardiac radioablation for treatment of incessant electrical storm: a case report from the RAVENTA trial.

Authors :
Kaestner L
Boda-Heggemann J
Fanslau H
Xie J
Schweikard A
Giordano FA
Blanck O
Rudic B
Source :
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] [Strahlenther Onkol] 2023 Nov; Vol. 199 (11), pp. 1018-1024. Date of Electronic Publication: 2023 Sep 12.
Publication Year :
2023

Abstract

Background: Electroanatomical mapping (EAM)-guided stereotactic arrhythmia radioablation (STAR) is a novel noninvasive therapy option for patients with monomorphic ventricular tachycardia (VT) refractory to antiarrhythmic drugs and/or urgent catheter ablation (CA). Data on success rates in an emergency situation such as electrical storm (ES) are rare. We present a case of a patient with an initially very poor life expectancy after extensive myocardial infarction with therapy-resistant ES, not amendable for further antiarrhythmic drug therapy, implantable cardioverter-defibrillator implantation, or repeated CA who was introduced to the radiation oncology department for emergency STAR as a bail-out therapy.<br />Methods: Target volume definition and transfer from EAM to CT were validated and quality assured with a semi-automatic, dedicated visualization tool (CARDIO-RT). Emergency STAR was performed with 25 Gy in the framework of the RAVENTA study. The VT burden gradually decreased after STAR; however, a second VT morphology occurred, which was successfully treated with EAM-guided CA 12 days after STAR.<br />Results: The second EAM-guided CA showed areas of low voltage in the irradiated segments, indicating a precise targeting and early functional response to STAR. The patient remained free of any VT recurrence or any radiation-related toxicities and in good general condition during the recent follow-up of 18 months.<br />Conclusion: The case highlights the possible approach, caveats, difficulties, and prognosis of a patient severely affected by therapy-resistant VT in whom CA could not lead to VT suppression. Further studies of putative mechanisms of STAR in the acute and chronic phase of this novel therapy are warranted.<br /> (© 2023. The Author(s).)

Details

Language :
English
ISSN :
1439-099X
Volume :
199
Issue :
11
Database :
MEDLINE
Journal :
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
Publication Type :
Academic Journal
Accession number :
37698592
Full Text :
https://doi.org/10.1007/s00066-023-02136-z